India stays on USTR priority watch list on IPR

India continues to figure on the USTR Priority Watch List in the 2026 Special 301 Report, published April 30, 2026 — a position it has held continuously sinc...

What Happened

India continues to figure on the USTR Priority Watch List in the 2026 Special 301 Report, published April 30, 2026 — a position it has held continuously since the 1990s.
The 2026 report places six countries on the Priority Watch List: Chile, China, India, Indonesia, Russia, and Venezuela.
Vietnam was designated a Priority Foreign Country (PFC), the most serious tier, for the first time in 13 years; the USTR is expected to decide within 30 days whether to open a formal Section 301 investigation.
Nineteen countries are on the Watch List, including the European Union (newly added) and Canada; Argentina and Mexico were downgraded from Priority Watch List to Watch List after showing improvement.
Specific concerns about India include long delays in patent approval, "excessive reporting requirements," prolonged patent opposition procedures, and high levels of piracy and counterfeiting.
India amended its patent rules in 2024 to reduce procedural burdens, but this did not result in removal from the Priority Watch List.

Static Topic Bridges

Special 301 and the WTO TRIPS Architecture

The Special 301 Report operates alongside, but outside, the WTO's dispute settlement system. The WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS, 1994) sets minimum standards for IP protection that all WTO members must meet. The Special 301 process, by contrast, is a unilateral US mechanism that evaluates not just TRIPS compliance but also "TRIPS-plus" standards — higher IP protections that the US pharmaceutical and technology industries seek globally, such as extended data exclusivity periods, broader patentability criteria, and stronger enforcement mandates.

TRIPS (1994): Part of the Uruguay Round agreements establishing the WTO; sets minimum IP standards including 20-year patent terms.
Doha Declaration on TRIPS and Public Health (2001): Reaffirmed TRIPS flexibilities, including compulsory licensing, for public health emergencies.
"TRIPS-plus" standards: IP protections beyond what TRIPS requires; often embedded in US bilateral free trade agreements.
India has consistently maintained that its IP framework is TRIPS-compliant and resists TRIPS-plus demands as inimical to generic medicine access.
The Special 301 Report cannot by itself compel India to change its laws; it serves as a pressure document and a precursor to potential Section 301 investigations.

Connection to this news: India's continued placement on the Priority Watch List reflects the core tension between TRIPS-plus standards sought by the US and TRIPS-compliant flexibility exercised by India — a divide that has persisted for three decades without resolution through either WTO dispute settlement or bilateral negotiation.

India's Generic Pharmaceutical Industry: Global Significance

India is often called the "pharmacy of the world." Its generic pharmaceutical sector is the largest globally by volume, supplying essential medicines to low- and middle-income countries and to government health programmes in the US itself. The industry's competitiveness depends directly on India's patent law framework, particularly provisions that limit product patents and enable generics to enter the market sooner.

India supplies approximately 20% of global generic medicine by volume.
The US is one of the largest markets for Indian generic exports; Indian generics account for approximately 40% of generic drug demand in the US.
Generic medicines are typically 80–90% cheaper than branded equivalents.
The Indian pharmaceutical sector is valued at over $50 billion, with exports exceeding $25 billion annually.
Key USTR concerns include: Section 3(d) of the Patents Act (anti-evergreening provision), compulsory licensing under Section 84, and delays in patent examination at the Indian Patent Office.

Connection to this news: Any change to India's patent framework under US pressure would directly affect the cost and availability of generic medicines both domestically and globally, giving India's resistance to TRIPS-plus standards a public health dimension that extends well beyond bilateral trade politics.

Patent Evergreening and Section 3(d) of the Indian Patents Act

Patent evergreening refers to the practice of making minor modifications to an existing patented product — such as changing its salt form, particle size, or delivery mechanism — and seeking a new patent to extend market exclusivity beyond the original patent term. In the pharmaceutical context, this keeps brand-name drugs expensive long after the original research innovation has been adequately rewarded. Section 3(d) of India's Patents Act, introduced in 2005, addresses this by requiring proof of significantly enhanced therapeutic efficacy before granting patents on new forms of known substances.

Section 3(d): Enacted as part of the Patents (Amendment) Act 2005, India's TRIPS-compliant response to product patent obligations.
Novartis AG vs. Union of India (2013): The Supreme Court of India upheld Section 3(d), rejecting Novartis's patent claim for the cancer drug Imatinib Mesylate (Glivec) on the ground that the new crystal form did not demonstrate significantly enhanced efficacy over the known substance.
The Novartis judgment is considered a landmark in global IP law, affirming the legality of anti-evergreening provisions under TRIPS.
The USTR and US pharmaceutical groups have consistently argued Section 3(d) sets an unduly high patentability bar that discourages incremental pharmaceutical innovation.

Connection to this news: The 2026 Special 301 Report's continuation of pressure on India's pharmaceutical patent rules reignites the long-running debate over Section 3(d) — a provision whose legality was definitively settled by India's Supreme Court in 2013 but remains commercially contested by the US industry.

Key Facts & Data

India on Priority Watch List: continuously since the 1990s.
2026 Priority Watch List countries (6): Chile, China, India, Indonesia, Russia, Venezuela.
2026 Priority Foreign Country: Vietnam (first designation in 13 years).
2026 Watch List countries (19): includes EU, Canada, Pakistan, Brazil, among others.
Total trading partners reviewed in Special 301 2026: over 100.
India's pharmaceutical exports: over $25 billion annually.
India's share of global generic medicine supply: approximately 20% by volume.
Indian generics' share of US generic drug demand: approximately 40%.
Novartis vs. Union of India (2013): Supreme Court upheld Section 3(d), rejected evergreening patent on Glivec.
Natco Pharma vs. Bayer (2012): India's first compulsory licence; price of Sorafenib Tosylate fell from ~₹2.8 lakh to ~₹8,800 per month.
India amended patent rules in 2024 to improve procedural efficiency at the Indian Patent Office.